Stevie Threatt

872 total citations
37 papers, 664 citations indexed

About

Stevie Threatt is a scholar working on Genetics, Oncology and Biotechnology. According to data from OpenAlex, Stevie Threatt has authored 37 papers receiving a total of 664 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 14 papers in Oncology and 14 papers in Biotechnology. Recurrent topics in Stevie Threatt's work include Glioma Diagnosis and Treatment (17 papers), Cancer Research and Treatments (14 papers) and Virus-based gene therapy research (12 papers). Stevie Threatt is often cited by papers focused on Glioma Diagnosis and Treatment (17 papers), Cancer Research and Treatments (14 papers) and Virus-based gene therapy research (12 papers). Stevie Threatt collaborates with scholars based in United States and Thailand. Stevie Threatt's co-authors include Annick Desjardins, Henry S. Friedman, James E. Herndon, John H. Sampson, Allan H. Friedman, Katherine B. Peters, James J. Vredenburgh, David A. Reardon, Roger E. McLendon and Sridharan Gururangan and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Stevie Threatt

34 papers receiving 653 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stevie Threatt United States	12	501	198	171	169	140	37	664
Emese Filka United States	6	533 1.1×	240 1.2×	197 1.2×	202 1.2×	128 0.9×	9	672
Tim Cloughesy United States	9	431 0.9×	267 1.3×	142 0.8×	176 1.0×	191 1.4×	17	758
Kenneth Aldape United States	9	322 0.6×	286 1.4×	149 0.9×	135 0.8×	120 0.9×	21	648
Jan Sadones Belgium	12	428 0.9×	437 2.2×	348 2.0×	165 1.0×	151 1.1×	17	822
Koji Oka Japan	9	351 0.7×	310 1.6×	195 1.1×	138 0.8×	227 1.6×	23	727
Karina Eterovic United States	5	252 0.5×	207 1.0×	190 1.1×	107 0.6×	108 0.8×	6	545
Bertrand Actor Switzerland	9	282 0.6×	248 1.3×	98 0.6×	93 0.6×	95 0.7×	9	575
Y. Piao United States	6	261 0.5×	259 1.3×	175 1.0×	75 0.4×	125 0.9×	10	541
Sandra Boots‐Sprenger Netherlands	11	511 1.0×	425 2.1×	324 1.9×	157 0.9×	129 0.9×	12	829
Jeremy Rudnick United States	10	453 0.9×	178 0.9×	91 0.5×	108 0.6×	314 2.2×	36	844

Countries citing papers authored by Stevie Threatt

Since Specialization

Citations

This map shows the geographic impact of Stevie Threatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stevie Threatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stevie Threatt more than expected).

Fields of papers citing papers by Stevie Threatt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stevie Threatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stevie Threatt. The network helps show where Stevie Threatt may publish in the future.

Co-authorship network of co-authors of Stevie Threatt

This figure shows the co-authorship network connecting the top 25 collaborators of Stevie Threatt. A scholar is included among the top collaborators of Stevie Threatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stevie Threatt. Stevie Threatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Desjardins, Annick, Vidya Chandramohan, James E. Herndon, et al.. (2024). CTIM-13. D2C7-IT IN COMBINATION WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM). Neuro-Oncology. 26(Supplement_8). viii87–viii87. 1 indexed citations

Thompson, Eric M., Daniel Landi, Michael C. Brown, et al.. (2023). Recombinant polio–rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial. The Lancet Child & Adolescent Health. 7(7). 471–478. 29 indexed citations

Desjardins, Annick, Vidyalakshmi Chandramohan, Daniel Landi, et al.. (2022). A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).. Journal of Clinical Oncology. 40(16_suppl). e14015–e14015. 9 indexed citations

Peters, Katherine B., Gerald E. Archer, Pamela K. Norberg, et al.. (2019). Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.. Journal of Clinical Oncology. 37(15_suppl). e13526–e13526. 11 indexed citations

Johnson, Mark P., et al.. (2018). Convection-Enhanced Delivery in the Treatment of Glioblastoma. Seminars in Oncology Nursing. 34(5). 494–500. 14 indexed citations

Desjardins, Annick, John H. Sampson, Katherine B. Peters, et al.. (2016). Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.. Journal of Clinical Oncology. 34(15_suppl). 2061–2061. 16 indexed citations

Desjardins, Annick, John H. Sampson, Katherine B. Peters, et al.. (2015). Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.. Journal of Clinical Oncology. 33(15_suppl). 2068–2068. 5 indexed citations

Desjardins, Annick, John H. Sampson, Katherine B. Peters, et al.. (2014). Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM).. Journal of Clinical Oncology. 32(15_suppl). TPS2106–TPS2106. 2 indexed citations

Peters, Katherine B., Gordana Vlahovic, Lloyd M. Alderson, et al.. (2013). Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT.. Journal of Clinical Oncology. 31(15_suppl). e13015–e13015. 1 indexed citations

10.

Desjardins, Annick, John H. Sampson, Katherine B. Peters, et al.. (2013). Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.. Journal of Clinical Oncology. 31(15_suppl). 2094–2094. 1 indexed citations

11.

Sampson, John H., Annick Desjardins, Katherine B. Peters, et al.. (2013). 107 Dose-Finding and Safety Study of an Oncolytic Polio/Rhinovirus Recombinant Against Recurrent Glioblastoma. Neurosurgery. 60(Supplement 1). 155–155. 2 indexed citations

12.

Reardon, David A., James J. Vredenburgh, Annick Desjardins, et al.. (2012). Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. Journal of Neuro-Oncology. 108(3). 499–506. 28 indexed citations

13.

Vredenburgh, James J., Annick Desjardins, David A. Reardon, et al.. (2011). The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma. Clinical Cancer Research. 17(12). 4119–4124. 112 indexed citations

14.

Reardon, David A., Annick Desjardins, Katherine B. Peters, et al.. (2011). Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer. 117(23). 5351–5358. 69 indexed citations

15.

Desjardins, Annick, David A. Reardon, Katherine B. Peters, et al.. (2011). A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. Journal of Neuro-Oncology. 105(3). 601–606. 14 indexed citations

16.

Reardon, David A., Annick Desjardins, Katherine B. Peters, et al.. (2011). Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. Journal of Neuro-Oncology. 107(1). 155–164. 108 indexed citations

17.

Vredenburgh, James J., Annick Desjardins, John P. Kirkpatrick, et al.. (2010). Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated With Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme. International Journal of Radiation Oncology*Biology*Physics. 82(1). 58–66. 66 indexed citations

18.

Reardon, David A., Annick Desjardins, Katherine B. Peters, et al.. (2010). Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Journal of Neuro-Oncology. 103(2). 371–379. 74 indexed citations

19.

Desjardins, Annick, David A. Reardon, S. Gururangan, et al.. (2009). Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG). Journal of Clinical Oncology. 27(15_suppl). e13004–e13004. 1 indexed citations

20.

Quinn, Jennifer A., James J. Vredenburgh, Jeremy N. Rich, et al.. (2006). Phase II trial of Gliadel plus O⁶-benzylguanine (O⁶-BG) for patients with recurrent glioblastoma multiforme. Journal of Clinical Oncology. 24(18_suppl). 1568–1568. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact